Showing posts with label Merck. Show all posts
Showing posts with label Merck. Show all posts

Sunday, March 13, 2011

BMJ Fails to Disclose Money Link to Vaccine Manufacturers

Considering we are experiencing another wave of pertussis in places where the vaccine was greatly utilized, just as we face more flu cases in vaccinated people, one rally has to see beyond the dogma of a failed paradigm.

The money wasted on vaccine programs can be better spent on improving access to health promoting foods that support your immune system and help you stay free from disease.  This is a well known public health dictate: host health status as a barrier to disease.
Alliance for Human Research Protection
A Catalyst for Debate
www.ahrp.org
The editor in chief of the BMJ acknowledges that AHRP was right to criticize the BMJ and its editor for failing to disclose to its readership, the BMJ financial ties to Merck--manufacturer of 13 vaccines. She also acknowledges income from GSK--manufacturer of several vaccines as well. 
http://www.bmj.com/content/342/bmj.d1335/reply#bmj_el_251470 
"Thank you for giving me an opportunity to respond to Vera Hassner Sharav's comment, [1] which for those of you who haven't seen it is reproduced below.
http://www.ahrp.org/cms/content/view/766/9/  
Although Vera's claims may seem far-fetched on this occasion, she is right that we should have declared the BMJ Group's income from Merck as a competing interest to the editorial (and the two editor's choice articles) that accompanied Brian Deer's series on the Secrets of the MMR scare.[2] [3] [4] We should also, as you say, have declared the group's income from GSK as a competing interest in relation to these articles. We will publish clarifications." 
However, her statement, "We didn't declare these competing interests because it didn't occur to us to do so " is startling. How seriously are we to take her strongly articulated stance against researchers who fail to disclose their financial conflicts of interest--if she doesn't recognize her journal's blatant conflict of interest?
Either she is being disingenuous or downright cynical about the BMJs declared stand against financial conflicts of interest that are undermining the integrity of medical research reports, and its own clandestine partnerships with industry.
Let's be clear: financial conflicts of interest ALWAYS influence the position one defends-- human nature is no different between politicians whose campaign chests are filled by vested interests, government officials, or academics who have grown dependent on financial support from special interests. Each delivers the service for which he /she is paid.

Monday, February 14, 2011

Dr. Wakefield: Was Attack Based on Conflict of Interest?

Quick Vaccine Facts

As reported by the New England Journal of Medicine - 35% of adverse reports for rheumatoid arthritis are associated with MMR.

Rubella vaccine caused 55% of RA cases 1991-1998 in girls.

1 of 3 damaged neurologically from DPT;  35,000 yearly.

Pertussis: Babies die 7 times greater within 3 days of vaccination.  Reported as SIDS.  Journal of Pediatrics shows only 40-45% non-sustained effectiveness.  In an Ohio outbreak, 82% of those vaccinated developed the disease.
Is it just conceivably possible, that the BMJ's decision to commission and publish Brian Deer's series of  articles attacking Dr. Andrew Wakefield's personal and scientific integrity--without giving him an opportunity to defend himself--and to lend its unwavering editorial endorsement to the charges--might be influenced by a SIGNIFICANT financial conflict of interest? 

In 2008, the pharmaceutical giant, Merck, signed a partnership agreement with the BMJ Group that effectively gave the company control of 350 interactive continuing medical education courses in over 20 medical therapy areas?

In 2009, The Lancet also entered into a Merck partnership. 

"This unique partnership will change the face of medical education in Europe and beyond, allowing users access to most of BMJ Learning's library of 'Continuing Medical Education' (CME) and 'Continuing Professional Development' (CPD) content. " 
More: http://www.thefreelibrary.com/MSD+Signs+Partnership+With+BMJ+Group.-a0180213953

Why did the BMJ conceal from readers--of both the Deer series and the BMJ editorial excoriating Dr. Andrew Wakefield, charging him with deliberate fraud and financial conflict of interest--the fact that the BMJ had a partnership with Merck, manufacturer of 13 vaccines--including the MMR vaccine, which is at the center of the Wakefield controversy?  

The BMJ editorial accompanying Deer's articles, did its best to lend authority to the vaccine industry (Merck's) perspective. In an introductory sound bite the editors declare: "Clear evidence of falsification of data should now close the door on this damaging vaccine scare."
Read more.... http://www.ahrp.org/cms/content/view/766/9/

Monday, January 17, 2011

No Need for Shingles Vaccine When NATURAL TX WORKS!

Here's some data for you to review if you are considering Shingles vaccine.  Just don't forget there are natural and effective ways to treat and often prevent shingles.  Why take a risk with a vaccine?

Zostavax is recommended for people 60 and older, and it only protects half of those vaccinated. The attenuated virus, which means it's still alive, just "weakened, is 14 times as potent as the chickenpox vaccine.
ZOSTAVAX is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella-zoster virus (VZV). ZOSTAVAX, when reconstituted as directed, is a suspension for subcutaneous administration. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV when reconstituted and stored at room temperature for up to 30 minutes.
Each dose contains 31.16 mg of sucrose, 15.58 mg of hydrolyzed porcine gelatin, 3.99 mg of sodium chloride, 0.62 mg of monosodium L-glutamate, 0.57 mg of sodium phosphate dibasic, 0.10 mg of potassium phosphate monobasic, 0.10 mg of potassium chloride; residual components of MRC-5 cells including DNA and protein; and trace quantities of neomycin and bovine calf serum. The product contains no preservatives.
Do not get this vaccine if you are allergic to any ingredients, many people are allergic to sugar and MSG and may not know it. FMI - http://www.novaccine.com/specific-vaccines/vaccine.asp?v_id=36

Tuesday, December 22, 2009

Corruption at its very best

If you, like so many, beliveve that there is no conflict of interest in what the FDA does in its incestuous involvement with Big PhRMA, then all you have to do is realize the height of corruption as Julie Gerberding comes to Merck, heading up its vaccine division.

This is a very clear example of the government-corporate revolving door policy.

When we have ethics in government, this sort of thing doesn't happen for at least three years follwoing government employment.

And we all know how influential Merck has been at CDC and FDA, especially over the recent boost to its bottom line from swie flu vaccine sales, at a time when Gerberding was still with CDC.  
Dr. Julie Gerberding Named President of Merck Vaccines

WHITEHOUSE STATION, N.J. - (Business Wire) Merck & Co., Inc. (NYSE: MRK) today announced that Dr. Julie Gerberding has been named president of Merck Vaccines, effective January 25, 2010.

Dr. Gerberding led the Centers for Disease Control and Prevention (CDC) as director from 2002 to 2009. During her tenure at CDC, Dr. Gerberding led the agency during more than 40 emergency response initiatives for health crises including anthrax bioterrorism, food-borne disease outbreaks, and natural disasters, and advised governments around the world on urgent public health issues such as SARS, AIDS, and obesity.

“Vaccines are a cornerstone of Merck's commitment to health and wellness," said Richard T. Clark, chairman and chief executive officer, Merck & Co., Inc. "We are delighted to welcome an expert of Dr. Gerberding's caliber to Merck. As a preeminent authority in public health, infectious diseases and vaccines, Dr. Gerberding is the ideal choice to lead Merck's engagement with organizations around the world that share our commitment to the use of vaccines to prevent disease and save lives."

"I’ve had the privilege in my previous work in academia and in the federal government to be a passionate advocate for public health priorities such as vaccines, which are an imperative component of global health development," said Dr. Gerberding. "I am very excited to be joining Merck where I can help to expand access to vaccines around the world."

Read complete story: http://www.earthtimes.org/articles/printpressstory.php?news=1098689

Friday, October 16, 2009

Merck now targeting men with Gardasil, boys weren't enough

UPDATE: 10/17/09
The Risks and Benefits of HPV Vaccination
What your doctor or other health care provider is required to tell you by law, before you get a jab, so you can engage in informed consent.

UPDATE: 10/16/09
We have been covering this issue on NHN since 2008, and of course we are providing the information to alert you to the issues. Today The U.S. Food and Drug Administration cleared the vaccine for use in males ages 9 to 26, Merck said in a statement.
Read an update from Bloomberg News

We do not believe this is a necessary vaccine for any one.
------------------------------
Original post date: 11/13/08

We can't encourage you enough to be very concerned about this vaccine and the mass marketing campaign associated with its promotion and use.

Do the research and get the facts before you get the jab.

Find other Gardasil and vaccine related articles via our search window.
Merck vaccine protects men from wart virus, too
By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) – A vaccine designed to protect women and girls from cervical cancer caused by a wart virus may protect men, too, maker Merck and Co reported on Thursday.

The Gardasil vaccine was 90 percent effective in preventing lesions, mostly sexually transmitted warts, caused by the virus in men, Anna Giuliano of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and colleagues found.

It was about 45 percent effective in preventing infection with the four strains of HPV that it targets.

"We see 90.4 percent efficacy is reducing external genital lesions in males related to these four types of HPV -- 6, 11, 16, 18," Giuliano said in a telephone interview.

"These are the only data evaluating efficacy of any HPV vaccine in preventing disease in males, and were presented for the first time this week at the European Research Organization on Genital Infection and Neoplasia International Multidisciplinary Conference," Merck said in a statement.

The human papilloma virus, or HPV, is the most common sexually transmitted disease in the world. About 20 million Americans currently are infected with HPV, according to the U.S. Centers for Disease Control and Prevention.

It is the main cause of cervical cancer, which kills 3,870 women a year in the United States and 300,000 globally.

It can also cause other types of cancer, including anal and penis cancer as well as mouth and neck cancer. The CDC estimates that HPV caused 25,000 cases of cancer a year in the United States between 1998 and 2003.

Gardasil and its rival, GlaxoSmithKline's Cervarix, are only approved for use in girls and women, but the companies are seeking new markets and some experts say it should be used in boys and men, to protect them and their future sexual partners.

Merck said it remains on track to submit a U.S. application by the end of the year for the use of Gardasil in males ages 9 to 26.

Giuliano's team tested 4,065 young men ages 16 to 26, giving them either vaccine or placebo, and then checking them every six months. Evidence suggests the vaccine has to be given before a person is ever infected with HPV to be effective.

While it protected fewer than half the cases of HPV infection as detected in the blood, the vaccine appeared to prevent the development of genital warts and a precancerous

condition called penile/perineal/perianal intraepithelial neoplasia or PIN.

"This opens up some really important questions for further research," Giuliano said. "The cancers in men, which are HPV related are really only now being understood."

It will also be important to study whether vaccinating men protects female sexual partners, she said.

(Editing by Eric Walsh and Maureen Bavdek)
Copyright © 2008 Reuters Limited. All rights reserved.

Sunday, September 27, 2009

Vioxx maker Merck drew up hit list

This representation of corporate culture is just one reason why US healthcare costs are so high. It has nothing to do with helping people be healthy and well, its all about the product at what ever the price.

Interestingly enough a Merck detail rep in Anchorage is know to me to have engaged in a similar deceptive practice while making willful false statements about some help I provided him.

I guess Merck seeks out the unethical and dishonest to fill the ranks of their employees, they'll do what ever it takes to keep their job, or harm someone else, when they know they are lying.

When I think how degraded the health industry has become at the expense of people, I still fondly recall our neighbor from childhood, one of the top MSD executives.
Milanda Rout | April 01, 2009
Article from: The Australian
An international drug company made a hit list of doctors who had to be "neutralised" or discredited because they criticised the anti-arthritis drug the pharmaceutical giant produced.

Staff at US company Merck &Co emailed each other about the list of doctors - mainly researchers and academics - who had been negative about the drug Vioxx or Merck and a recommended course of action.

IN-DEPTH COVERAGE: The Vioxx Trial

The email, which came out in the Federal Court in Melbourne yesterday as part of a class action against the drug company, included the words "neutralise", "neutralised" or "discredit" against some of the doctors' names.

It is also alleged the company used intimidation tactics against critical researchers, including dropping hints it would stop funding to institutions and claims it interfered with academic appointments.

"We may need to seek them out and destroy them where they live," a Merck employee wrote, according to an email excerpt read to the court by Julian Burnside QC, acting for the plaintiff.

Merck & Co and its Australian subsidiary, Merck, Sharpe and Dohme, are being sued for compensation by more than 1000 Australians, who claim they suffered heart attacks or strokes as a result of Vioxx.

The drug was launched in 1999 and at its height of popularity was used by 80 million people worldwide because it did not cause stomach problems as did traditional anti-inflammatory drugs.

It was voluntarily withdrawn from sale in 2004 after concerns were raised that it caused heart attacks and strokes and a clinical trial testing these potential side affects was aborted for safety reasons.

Lead plaintiff Graeme Peterson, 58, claims the drug caused him to have a heart attack in 2003 after he took it for back pain and arthritis every day from May 2001.

Merck last year settled thousands of lawsuits in the US over the effects of Vioxx for $US4.85billion ($7.14 billion) but made no admission of guilt.

The company is fighting the class action in Australia.

The Federal Court was told yesterday that Merck wanted to gain the backing of researchers and doctors - or "opinion leaders" - in the fields of arthritis to help promote the drug to medical professionals when it was launched in 1999.

Mr Burnside said internal emails in April 1999 from Merck staff showed the company was not happy with what some researchers and doctors were saying about the drug.

"It gives you the dark side of the use of key opinion leaders and thought leaders ... if (they) say things you don't like to hear, you have to neutralise them," he said. "It does suggest a certain culture within the organisation about how to deal with your opponents and those who disagree with you."

The court was told that James Fries, professor of medicine at Stanford University, wrote to the then Merck head Ray Gilmartin in October 2000 to complain about the treatment of some of his researchers who had criticised the drug.

"Even worse were allegations of Merck damage control by intimidation," he wrote, according to Mr Burnside.

"This has happened to at least eight (clinical) investigators ... I suppose I was mildly threatened myself but I never have spoken or written on these issues."

Mr Burnside told the court Dr Fries went on to describe instances of intimidation, including one colleague who thought his academic appointment had been jeopardised and another who received phone calls alleging "anti-Merck" bias.

Dr Fries said in the letter that Merck had been systematically playing down the side effects of Vioxx and said the company's behaviour "seriously impinges on academic freedom". The court was also told a rheumatologist on Merck's Australian arthritis advisory board was angry he did not find out about Merck's decision to withdraw Vioxx until an ABC journalist rang to tell him. Mr Burnside said James Bertouch wrote to other members of the board saying he was "extremely disillusioned" with the company.

"In every possible way the company exerted itself to present the impression to the world at large that Vioxx did not provide any increased cardio risk ... when (a) it probably would and (b) it probably did," he wrote, according to Mr Burnside.

Peter Garling, acting for Merck, accused Mr Peterson of not taking the drug Vioxx in the months leading up to his heart attack in December 2003.

He said Pharmaceutical Benefits Scheme figures showed he did not fill a Vioxx prescription for the drug in the two months before his heart attack.

Mr Garling put to Mr Peterson during his cross-examination that this was because he had retired from his job as a safety consultant and therefore he did not need to take Vioxx because his back pain lessened.

Mr Peterson denied this meant he was not taking the drug.

"No, I wouldn't accept that at all," he said. "I can remember taking Vioxx regularly."

The trial, before Justice Chris Jessop, continues.


Further reading on Corporations -

When I was first in college in the 60s, the popular book to read was "The Organization Man", now it seems that this is a replacement.
Gangs of America: The Rise of Corporate Power and the Disabling of Democracy by Ted Nace

"A good book to read is called: "The Gangs of America"; which chronicles how with about one dozen supreme court cases (because the northeastern railroads payed off congress to pack the Supreme Court with pro corporate constitutional personhood rights justices) that have given corporations with the "myth" of constitutional personhood....the second american revolution's central causes are twofold: the first being the federal reserve controlling our politics; business and quality of life through inflation and deflation and control of the issuance of money.....the second cause will be the corporate oligarchy and the mythic "rights" that have been fraudulently bestowed on the corporate entity in our nation beginning in the 1870's....if you don't believe me; purchase and read the book that I mentioned in the beginning of this paragraph....and make up your own mind....if we all work together we can get back to a nation where most of the American population is self employed; or work for small locally owned businesses; a nation where we are once again self reliant; and we can in this nation place the corporate charter model and the anti democratic and anti republican tendencies of it into the dust bin of history forever...."

Monday, March 23, 2009

Cancer drug 'fuels tumour growth'

A type of drug designed to stunt tumour growth has actually been found to fuel cancer if given at too low a dose.

Read about Cilengitide, another Merck creation. It's also targeted for prostate cancer use.

Someday the Big Pharma crowd will be stopped from all this creative cooking at the expense of life.

In the interim my hope would be that anyone treated with mainstream methods for cancer would stop and ask many more questions. It might save save your life.

Friday, November 14, 2008

Much Ado About Merck Marketing

I'd suggest the money spent on this fiasco be put to nutrition education in an effort to prevent and reverse diabetes rather than promote drug sales.
A group of labor unions is launching a campaign that accuses CVS Caremark Corp. of violating patient privacy and improperly pushing doctors to prescribe a costly prescription drug.

Change to Win, a group of unions that represents about six million workers, said CVS's pharmacy benefits management business has been urging doctors via a letter to add Merck & Co. diabetes drug Januvia to specific patients' treatments. The letter, obtained by the union group, said CVS identified the diabetes patients through a review of prescription-drug claims processed by its Caremark unit.

A line at the bottom of the letter says Merck paid for the mailing. Neither Merck nor CVS would say how much Merck paid, and the drug maker also declined to say whether the mailing boosted Januvia sales.

CVS said the union group's actions are rooted in a dispute about workplace rules. The unions represent several thousand CVS workers. The Woonsocket, R.I., company said the unions have been attacking CVS for more than a year, including objecting to two recent acquisitions.

Januvia is as much as eight times more expensive than many other diabetes treatments, according to a recent study. Some medical experts say patients may not need the drug and may respond just as well to older, cheaper treatments.

The CVS letter was previously reported by Phoenix Business Journal.

Change to Win says the Januvia letter is an example of CVS putting its interests ahead of the businesses that pay it to manage employee prescription-drug benefits. CVS became a big player in the pharmacy-benefits business when it acquired Caremark, then the nation's second-largest PBM, for about $27 billion in 2007.

A Merck spokeswoman said the Whitehouse Station, N.J., company paid for the mailing "to help inform physicians about additional treatment options." She added that "no personal information about patient participants in the plan are provided to Merck." The letters were sent by CVS Caremark, not Merck.

CVS said it does not improperly try to switch patients to more expensive drugs and protects the privacy of plan participants' health information. As for the Januvia mailing, CVS said it was part of a program to provide information to physicians and that doctors make the ultimate decision about prescribing a drug.

Employers and insurers hire PBMs with the goal of keeping costs low while providing access to a wide range of treatments.

In recent years, PBMs have been accused of favoring drugs that generate rebates and high profit margins. Six years ago, some patients complained about a letter from Longs Drug Stores urging the patients to switch to a new version of the osteoporosis treatment Fosamax. That mailing also was paid for by Merck.

The union campaign, set to be announced Friday, comes as CVS's PBM business has struggled. In its most recent quarterly earnings report, announced last month, revenue in the PBM unit fell about 1% to $10.6 billion.

Change to Win's executive director, Chris Chafe, said the goal of the CVS campaign is to change state laws to force PBMs to disclose to customers all payments or rebates they receive from drug companies; limit the amount of patient information the PBMs can disclose; and require that any switching of drugs results in lower costs for PBM customers.

Mr. Chafe said CVS was targeted because of its large role in the retail drug business and the PBM industry, and because the company manages prescription benefits of many union members. Change to Win's members include the Teamsters and the Service Employees International Union.

Write to David Armstrong at david.armstrong@wsj.com
http://online.wsj.com/article/SB122663485690627711.html?mod=todays_us_marketplace

Wednesday, November 5, 2008

Merck vaccine trail increased infection risk

This article points out vaccine failure. I reported on this blog at the time this report was first made. Now there is room for an update.

This experimental HIV vaccine was a Merck product, not unlike the Gardasil vaccine that is known to have caused death and higher risk of disease, without real promise of effectiveness, and no long term studies.

With advertising and marketing Merck and the FDA have made a killing of sorts, at the bank. This might be a good analogy for those of us that keep trying to explain that vaccines aren't all they are built up to be. They do make people sick.

And here's my opportunity to make another plug for the trial I'd like to run with supplements to show they can stop the conversion of HIV to AIDS.

If Bill Gates won't give me a grant perhaps Merck will. Just wish Sir Elton would read this, I'd like his money better. William and Harry might come through so we can dedicate this to their Mum.
Experimental HIV vaccine may have increased infection risk
Mon Nov 3, 2008
WASHINGTON (AFP) – Trials of a once-promising experimental HIV vaccine were cut short in 2007 because the drug may have increased the likelihood of HIV infection rather than preventing it, according to a new study.

The HIV-1 vaccine, which raised hopes in the fight against AIDS as it was being developed by US pharmaceutical giant Merck and Co., was undergoing second stage trials when the problem was discovered in September 2007, said researchers at the Montpellier Institute of Molecular Genetics in France.

The vaccine relied on a modified form of a common cold virus -- Adenovirus 5 (Ad5) -- to carry elements of HIV (Human immunodeficiency virus) into the body.

The smaller HIV parts, the Merck trials contended, would trigger the human immune system to start fighting off later infection with the virus.

One of main worries about the approach was that widespread immunity to the vaccine might cause the drug to be rejected by the body before an effective anti-HIV response could develop.

But three years after the first trial, researchers discovered that more of the vaccine recipients who had prior immunity to the Ad5 virus had been infected with HIV than those not exposed to the vaccine, according to the study, published online in the Journal of Experimental Medicine.

The presence of long-lasting antibodies specifically catering to the Ad5 virus, generated during natural infections with the common cold, could have altered the response to the HIV vaccine, the study said.

HIV infection spread through cell cultures three times faster in the presence of antibodies from individuals immune to the Ad5 virus, because the HIV virus came in contact with more of its preferred "T" cells -- prompted to grow by the vaccine -- to infect.

The study said the vaccine reached the second phase of its trials because primates, used in the first phase, do not naturally come into contact with the human common cold, so the problem went unrecognized.

The vaccine prototype was tested on 700 HIV-negative persons in five hospitals in South Africa between February and September 2007, in the first clinical HIV trial of its magnitude ever conducted in Africa.

Meanwhile, tests had been conducted since 2004 in the United States, Australia, Peru, Brazil and Puerto Rico.

HIV can lead to acquired immunodeficiency syndrome (AIDS).

According to the World Health Organization, 33 million people around the world are infected with the AIDS virus, mostly in the sub-Sahara Africa.

Some two million people died worldwide of AIDS in 2007.

Copyright © 2008 Agence France Presse.

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Macys Printable Coupons